|
G. Lambert was awarded a PhD in Pathophysiology from the University of Paris in 1998. He specialized in lipidology, as a post-doctoral fellow at the Molecular Disease Branch of the NIH (Bethesda MD, USA) and as a senior research fellow at the Heart Research Institute (Sydney, Australia).
Since 2002, G. Lambert has conducted seminal research projects on PCSK9, a protein that targets the LDL receptor for intracellular degradation, and the target of novel cholesterol lowering therapies. He has investigated the cellular pathways by which PCSK9 modulates the circulating levels of lipoprotein (a). Gilles Lambert is currently Professor in Cell Biology and Biochemistry at the University of La Réunion Medical School (France) and a principal investigator at Inserm UMR1188 DéTROI laboratory Scientific summaryMy current research goals are to elucidate the genetic and the metabolic determinants of elevated lipoprotein (a), a highly atherothrombotic lipoprotein species.
|
PUBLICATIONS
1. Chemello K, Beeské S, Tran TTT, Blanchard V, Villard E, Poirier B, LeBail JC, Dargazanli G, Ho-Van-Guimbal S, Boulay D, Bergis O, Pruniaux MP, Croyal M, Janiak P, Guillot E, G Lambert (2020) “Lipoprotein (a) Cellular Uptake and Hepatic Capture are Insensitive to PCSK9 Inhibition with Alirocumab.” JACC Basic Transl. Sci. 5, 459-457.
2. B Nativel, S Ramin-Mangata, D Couret, C Planesse, M Roche, A Gallo, O Meilhac, G Lambert and S Bourane (2021) “PCSK9 inhibition in hyperglycemic mice increases the risk of hemorrhagic transformation of ischemic stroke” Stroke 52, e545-e547.
3. V Blanchard, K Chemello, T Hollstein, C Chong-Hong-Fong, F Schumann, T Grenkowitz, B Nativel, S Coassin, M Croyal, U Kassner, C Lamina, E Steinhagen-Thiessen, and G Lambert (2022) “The size of apolipoprotein (a) is an independent determinant of the reduction in lipoprotein (a) induced by PCSK9 inhibitors.” Cardiovascular Research 118, 2103-2111.
4. S Coassin, K Chemello, I Khantalin, L Forer, P Döttelmayer, S Schönherr, R Grüneis, C Chong-Hong-Fong, B Nativel, S Ramin-Mangata, A Gallo, M Roche, B Mühlegger, C Gieger, A Peters, J Zschocke, C Marimoutou, O Meilhac, C Lamina, F Kronenberg, V Blanchard, G Lambert. (2022) “Genome-wide Characterization of a Highly Penetrant Form of Hyperlipoprotein(a)emia Associated with Genetically Elevated Cardiovascular Risk.” Circulation Genomic and Precision Medicine 15, e003489.
5. K Chemello, A Gallo, AF Guedon, R Techer, M Croyal, MJ Swietek, O Meilhac, P Amarenco, G Lambert (2023) “Lipoprotein(a): a residual cardiovascular risk factor in statin-treated stroke survivors - Insights from the SPARCL trial” JACC Adv. 2, 100557.
2. B Nativel, S Ramin-Mangata, D Couret, C Planesse, M Roche, A Gallo, O Meilhac, G Lambert and S Bourane (2021) “PCSK9 inhibition in hyperglycemic mice increases the risk of hemorrhagic transformation of ischemic stroke” Stroke 52, e545-e547.
3. V Blanchard, K Chemello, T Hollstein, C Chong-Hong-Fong, F Schumann, T Grenkowitz, B Nativel, S Coassin, M Croyal, U Kassner, C Lamina, E Steinhagen-Thiessen, and G Lambert (2022) “The size of apolipoprotein (a) is an independent determinant of the reduction in lipoprotein (a) induced by PCSK9 inhibitors.” Cardiovascular Research 118, 2103-2111.
4. S Coassin, K Chemello, I Khantalin, L Forer, P Döttelmayer, S Schönherr, R Grüneis, C Chong-Hong-Fong, B Nativel, S Ramin-Mangata, A Gallo, M Roche, B Mühlegger, C Gieger, A Peters, J Zschocke, C Marimoutou, O Meilhac, C Lamina, F Kronenberg, V Blanchard, G Lambert. (2022) “Genome-wide Characterization of a Highly Penetrant Form of Hyperlipoprotein(a)emia Associated with Genetically Elevated Cardiovascular Risk.” Circulation Genomic and Precision Medicine 15, e003489.
5. K Chemello, A Gallo, AF Guedon, R Techer, M Croyal, MJ Swietek, O Meilhac, P Amarenco, G Lambert (2023) “Lipoprotein(a): a residual cardiovascular risk factor in statin-treated stroke survivors - Insights from the SPARCL trial” JACC Adv. 2, 100557.